![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de categorías
AlcoholismoAlzheimer Y ParkinsonAnalgésicosAntialérgicasAntibióticosAnticonceptivosAnticonvulsivosAntidepresivosAntifúngicosAntiinflamatoriosAntiparasitariosAntiviralesArtritisAsmaCirugíaColesterolCuidados De La PielCuidados De Los OjosCáncerDiabetesDisfunción EréctilDiuréticosEnfermedad CardiovascularEnfermedades GastrointestinalesEnfermedades GenitourinariasEnfermedades NeurológicasMedicamentos V I HMigrañasOsteoporosisPresión ArterialPérdida De PesoRelajantes MuscularesSalud FemeninaSalud MasculinaTracto RespiratorioTrastornos Mentales 09 May 2012 16:42:40
4 Reasons Merck Will Break $40 By 20134 Reasons Merck Will Break $40 By 2013 Seeking Alpha Much of this is thanks to the fact that Merck has been more fiscally responsible, by working with lower marketing and production costs, while at the same time, cutting the prices on Hyzaar and Cozaar , two blood pressure medications that have not been ...
07 May 2012 04:33:53
Top global pharma cos post sales growth of just 3.4%, but net profit up by ...Top global pharma cos post sales growth of just 3.4%, but net profit up by ... pharmabiz.com ... Lovenox (Sanofi-aventis), Remicade (Merck), Plavix (Sanofi-aventis), Aranesp and Epogen (Amgen), Vytorin (Merck), Aprovel CoAprovel (sanofi-aventis), Cozaar Hyzaar (Merck) Procrit Eprex (J&J), Pegasys (Roche) and Zometa (Novartis) received setback ...
30 Apr 2012 20:50:18
1 Unexcitingly Good Dividend Play1 Unexcitingly Good Dividend Play DailyFinance Right now it's Merck's heart drugs Cozaar and Hyzaar, which plummeted 21% in the first quarter. Upcoming is top-selling Singulair, which will begin seeing generic competition in the US in August. The company hopes to keep 2012 sales constant compared ...
30 Apr 2012 09:54:30
Strong profit growth and Zetia patent win for Merck & CoStrong profit growth and Zetia patent win for Merck & Co Pharma Times Revenues from the antihypertensives Cozaar (losartan) and Hyzaar (losartan plus hydrochlorothiazide) fell 21% to $336 million, due to generic competition. The anti-inflammatory Remicade (infliximab), the Johnson & Johnson drug which Merck sells outside ...
27 Apr 2012 17:26:52
Utilidad de Merck supera expectativas por control de costosUtilidad de Merck supera expectativas por control de costos El Economista.com.mx Cozaar , un medicamento para la presi n sangu nea que ahora se enfrenta a la competencia de los gen ricos, tambi n redujo sus resultados, con ventas que cayeron 21% a 336 millones de d lares. Las ventas de Gardasil, una vacuna para la prevenci n del ...
27 Apr 2012 16:30:40
Merck affiche des résultats trimestriels en hausseMerck affiche des r sultats trimestriels en hausse Capital.fr Les r sultats de Merck ont aussi t affect s par la chute de 21% des ventes du Cozaar , un m dicament contre la tension art rielle qui fait face la concurrence des g n riques. A l'inverse, les ventes du Gardasil, un vaccin destin pr venir le virus ...
27 Apr 2012 13:20:21
Merck Posts Big Q1 Profit Jump on Lower Charges ABC News Merck Posts Big Q1 Profit Jump on Lower Charges ABC News Together, they brought in $1.31 billion, helping make up for generic competition continuing to slash sales of former blockbusters Cozaar and Hyzaar, for high blood presure. Gardasil and HIV drug Isentress both had double-digit sales growth. Merck Beats by a Penny; Affirms View - Analyst Blog Merck Announces First-Quarter 2012 Financial Results Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call Transcript |
|
Choose Your language:
Site search
Testimonios de nuestros clientes
Recibí el encargo muy rápido. Verdaderamente era impressoné por la velocidad de entrega. - Mike
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Bestsellers|Nuestra política|F.A.Q.|Testimonios de nuestros clientes|Contacto|Sitemap |
|
|
|
|
| |